B and T Cell Gene Rearrangement, Bone Marrow
Immunoglobulin gene rearrangement occurs physiologically in B lymphoid cells during their maturation. This recombination allows for an almost unlimited diversity of immune responses, and responses to literally millions of antigens. Lymphomas and lymphocytic leukemia are neoplastic disorders. The diagnosis of these disorders requires the demonstration of a clonal expansion of lymphoid or plasma cells. In general, the percentage of B lymphocytes with identical immunoglobulin heavy chain gene rearrangements is very low. In lymphoid and plasma cell malignancies, however, the clonal expansion of one population leads to a large number of cells with identical B-cell immunoglobulin heavy chain gene rearrangements.
Cell clonality in lymphoid malignancy can be defined in several ways. Light microscopy morphology can detect a neoplastic proliferation, but can not ascertain specific genetic clonality, which requires identification of a specific repetitive molecular change in the clonal cell population. Immunopathological methods such as flow cytometry (where a monoclonal B-cell population is defined by the presence of monoclonal surface immunoglobulin), or cytogenetics (which can identify specific repetitive chromosomal abnormalities) are required for the diagnosis of clonality. Because B-cells normally express either a kappa light chain or a lambda light chain, a population can be selectively quantitated by the presence of either kappa or lambda light chain. If B-cells carry only kappa or lambda light chain, the population is then known as monoclonal, and the lymphoid proliferation is neoplastic. In contrast to a neoplastic monoclonal B-cell population, a benign reactive B-cell population contains a mixture of B-cells with either kappa light chain or lambda light chain. For T-cell neoplasms, the immuopathological marker of clonality is T-cell receptor gene rearrangement.
Abnormal cell surface antigen expression is often seen with both B- and T-cell clonal proliferations (neoplasms). In addition, clonality of both B- and T-cells often correlates with cytogenetic abnormalities in which the clonal population possesses chromosomal alterations such as translocations, deletions, inversions, and others.
Gene rearrangement is considered to be the “gold standard” for determining clonality and is utilized primarily when clonality cannot be determined by immunopathological methods. It should be noted that detection of gene rearrangement is not 100% specific for a neoplastic process. Certain reactive conditions can show this abnormality.
- Diagnosis of B-cell and T-cell lymphoid neoplasms (lymphomas, leukemias, myeloma and some B-cell immunoglobulinopathies)
- Evaluation of clonality of a lymphoid (B or T) or plasma cell population
- Identifying cell lineage (B or T) of a neoplastic lymphoid cell population
- Disease management and therapy monitoring
- Follow up and monitoring for persistent or recurrent neoplasm
Positive in:
- B- and T-cell lymphoid lymphomas
- B- and T-cell lymphoid leukemias
- Positive in some autoimmune disorders such as Sjögren syndrome, rheumatoid arthritis
- Positive in some immunodeficiency states (transplant and HIV patients)
- Some dermatologic disorders such as Sezary syndrome, mycosis fungoides, lymphomatoid papulosis and possibly pityriasis lichenoides
If the immunoglobulin (B cell) or T-cell receptor (T cells) genes are rearranged in a monoclonal fashion, then the cell population in question is considered monoclonal (genetically identical) and therefore neoplastic and not reactive.
Negative for gene rearrangement (an interpretive report is usually included with results)
Flow Cytometry (immunophenotyping), Restriction fragment length polymorphism, polymerase chain reaction (PCR), fluorescent in situ hybridization (FISH).
Bone Marrow EDTA (Lavender).
Stability
- Ambient: 1-3 days
- Refrigerated: 5-7 days
- Frozen: Unacceptable
- Clin Lab Sci. 1993 Sep-Oct;6(5):291-4. [PMID: 10146555]
- Pathology. 2001 May;33(2):222-5. [PMID: 11358058]
- J Mol Diagn. 2002;4:81. [PMID: 11986398]
- Pathol Oncol Res. 2007;13(3):209-14. [PMID: 17922050]
- Engl J Med. 2003;348:1777. [PMID: 12724484]